Arkolith/Insider Trading/RVNC/Form 4

Jordan Erica

Chief Commercial OfficerRevance Therapeutics, Inc. (RVNC) · full profile →Form 4 · filed Feb 6, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 6, 2025Disposed to issuer(D)108K——0
Feb 4, 2025Tender(U)7K$3.65$25K108K

Transaction Codes

D
Disposition to the issuer
U
See SEC Form 4 code table

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-015356) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML